Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Cetuximab with Re-Irradiation for Relapsed/Refractory Gliomas
NCT02800486Phase 2Recruiting
- Sponsor
- Northwell Health
- Start
- May 2016
- Primary completion
- May 2035
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), oligoastrocytoma, sponsored by Northwell Health. Started May 2016; status: recruiting.
02
Drugs
cetuximab
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)oligoastrocytoma
Beyond the preview
Go deeper on NCT02800486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02800486.